C difficile risk
Oral Bioavailability


Defined criteria for use and/or important safety considerations. See below for more information.

1 g IV q24h

2 g IV q12h

2 g IV q24h

2 g IV q12h

General Information

  • EMPIRIC therapy of severely ill patients with suspected Gram-negative infection

  • Documented Gram-negative infection resistant to 1st and 2nd generation cephalosporins

  • Meningitis, brain abscess

  • Spontaneous bacterial peritonitis, community-acquired secondary peritonitis (or hospital acquired with no previous antimicrobial therapy), or intra-abdominal abscess.

  • Salmonella

  • Community acquired pneumonia

  • Gonorrhea

  • Pelvic Inflammatory Disease, Epididymitis

  • Some endocarditis infections

  • Synergy in some Enterococci endocarditis infections, particularly if gentamicin is contraindicated

  • Complicated Lyme infections

Does not cover Listeria, Pseudomonas, ESBLs or AmpC producing Enterobacteriaceae

Avoid in patients with biliary sludging or cholestatic hepatitis (see Cefotaxime)

Avoid for serious Citrobacter or Enterobacter infections, even if reported as susceptible

  • Allergy/rash (immediate or delayed)

  • Cytopenias

  • Eosinophilia

  • Hepatic & renal laboratory abnormalities

  • Pseudocholelithiasis: more likely if on TPN and using ≥ 2g/day

  • Drug induced immune thrombocytopenia

  • Prolonged QTC with concomitant lansoprazole

Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.